+

WO1999020305A8 - Vaccins veterinaires - Google Patents

Vaccins veterinaires

Info

Publication number
WO1999020305A8
WO1999020305A8 PCT/AU1998/000865 AU9800865W WO9920305A8 WO 1999020305 A8 WO1999020305 A8 WO 1999020305A8 AU 9800865 W AU9800865 W AU 9800865W WO 9920305 A8 WO9920305 A8 WO 9920305A8
Authority
WO
WIPO (PCT)
Prior art keywords
veterinary vaccines
vaccines
veterinary
lambs
sheep
Prior art date
Application number
PCT/AU1998/000865
Other languages
English (en)
Other versions
WO1999020305A1 (fr
Inventor
Richard Buchta
Christopher Leigh Schwartzkoff
Philip Ralph Lehrbach
Original Assignee
Fort Dodge Australia Pty Limit
Richard Buchta
Christopher Leigh Schwartzkoff
Philip Ralph Lehrbach
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9722035.4A external-priority patent/GB9722035D0/en
Application filed by Fort Dodge Australia Pty Limit, Richard Buchta, Christopher Leigh Schwartzkoff, Philip Ralph Lehrbach filed Critical Fort Dodge Australia Pty Limit
Priority to US09/509,961 priority Critical patent/US6524592B2/en
Priority to AU96161/98A priority patent/AU753804B2/en
Priority to PCT/AU1998/000865 priority patent/WO1999020305A1/fr
Priority to EP98949828A priority patent/EP1023083A4/fr
Priority to NZ503636A priority patent/NZ503636A/en
Priority to CA2307000A priority patent/CA2307000C/fr
Publication of WO1999020305A1 publication Critical patent/WO1999020305A1/fr
Publication of WO1999020305A8 publication Critical patent/WO1999020305A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des vaccins vétérinaires qui sont destinés à la prévention de maladies clostridiales affectant les moutons (et agneaux) et qui assurent une immunité efficace pendant au moins un an après une seule injection ou dose.
PCT/AU1998/000865 1997-10-17 1998-10-16 Vaccins veterinaires WO1999020305A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US09/509,961 US6524592B2 (en) 1997-10-17 1998-10-16 Veterinary vaccines
AU96161/98A AU753804B2 (en) 1997-10-17 1998-10-16 Veterinary vaccines
PCT/AU1998/000865 WO1999020305A1 (fr) 1997-10-17 1998-10-16 Vaccins veterinaires
EP98949828A EP1023083A4 (fr) 1997-10-17 1998-10-16 Vaccins veterinaires
NZ503636A NZ503636A (en) 1997-10-17 1998-10-16 Vaccines for the prevention of clostridial diseases of sheep that provide effective immunity for up to a year or more from a single dose
CA2307000A CA2307000C (fr) 1997-10-17 1998-10-16 Vaccins veterinaires

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9722035.4A GB9722035D0 (en) 1997-10-17 1997-10-17 Veterinary vaccines
GB9722035.4 1997-10-17
PCT/AU1998/000865 WO1999020305A1 (fr) 1997-10-17 1998-10-16 Vaccins veterinaires

Publications (2)

Publication Number Publication Date
WO1999020305A1 WO1999020305A1 (fr) 1999-04-29
WO1999020305A8 true WO1999020305A8 (fr) 1999-07-08

Family

ID=25641911

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1998/000865 WO1999020305A1 (fr) 1997-10-17 1998-10-16 Vaccins veterinaires

Country Status (5)

Country Link
EP (1) EP1023083A4 (fr)
AU (1) AU753804B2 (fr)
CA (1) CA2307000C (fr)
NZ (1) NZ503636A (fr)
WO (1) WO1999020305A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2824279B1 (fr) * 2001-05-04 2004-05-28 Seppic Sa Emulsion e/h concentree
FR2824269B1 (fr) * 2001-09-03 2012-03-02 Seppic Sa Composition adjuvante constituee de 1% a 15% de tensioactifs a hlb global compris entre 5 et 8 et de 85% a 99% de corps gras
NZ569627A (en) * 2005-12-15 2012-01-12 Hancroft Pty Ltd The use of virginiamycin for preventing reduced feed intake and treating laminitis, fermentative acidosis, equine grass sickness and pulpy kidney
FR2903602B1 (fr) * 2006-07-12 2012-10-26 Seppic Sa Formulation injectable a liberation prolongee de principes actifs, procede pour sa preparation
FR2922767B1 (fr) 2007-10-24 2009-12-18 Seppic Sa Procede de preparation d'une composition vaccinale comprenant au moins un antigene et au moins un adjuvant.
CN106177935A (zh) * 2016-08-19 2016-12-07 齐鲁动物保健品有限公司 一种反刍动物梭菌病四联灭活疫苗及其制备方法
GB201718251D0 (en) * 2017-11-03 2017-12-20 Univ Sydney Vaccine Compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1128325A (en) * 1964-11-11 1968-09-25 Wellcome Found Improvements in water-in-oil emulsion vaccines
US3843451A (en) * 1970-08-20 1974-10-22 Burroughs Wellcome Co Microorganism production
FR2649012B1 (fr) * 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
FR2717694B1 (fr) * 1994-03-22 1996-05-03 Seppic Sa Une composition comprenant un plasmide recombinant et ses utilisations comme vaccin et médicament.
US5814321A (en) * 1995-11-30 1998-09-29 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Oil adjuvant vaccine and method for preparing same
GB9626865D0 (en) * 1996-12-24 1997-02-12 Cyanamid Websters Pty Limited Veterinary vaccines

Also Published As

Publication number Publication date
CA2307000A1 (fr) 1999-04-29
WO1999020305A1 (fr) 1999-04-29
NZ503636A (en) 2002-05-31
EP1023083A1 (fr) 2000-08-02
CA2307000C (fr) 2011-01-04
AU9616198A (en) 1999-05-10
AU753804B2 (en) 2002-10-31
EP1023083A4 (fr) 2006-06-14

Similar Documents

Publication Publication Date Title
GB2322801B (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
ZA975943B (en) Aqueous formulations of peptides.
HK1027280A1 (en) Plant extracts for the treatment of increased boneresorption.
AUPM969994A0 (en) Equine anthelmintic formulations
HK1047575A1 (en) Indanyl-substituted benzole carbonamide, method for the production of the same, use thereof as a medicament and pharmaceutical preparations containingthe same.
ZA98361B (en) Hypodermic injection system.
ZA967745B (en) Pharmaceutical formulations.
ZA969722B (en) Pharmaceutical formulations.
EP0671902A4 (fr) THERAPIE DES TOXI-INFECTIONS AU -i(CLOSTRIDIUM).
AU3699397A (en) Polynucleotide vaccine formula for treating dog diseases, particularly respiratory and digestive diseases
EP0680337A4 (fr) Procedes et compositions pour application directe a forte concentration d'anticorps, produisant une immunite passive.
AU3772797A (en) Polynucleotide vaccine formulation against pathologies of the horse
DE68904300D1 (de) Medizinische aerosolformulierungen.
DE69419519D1 (de) Riechstoffe formulierungen
EP0640097A4 (fr) Compositions et procedes de vaccination contre les coronavirus.
DZ2283A1 (fr) Composition de vaccin.
WO1999020305A8 (fr) Vaccins veterinaires
ES2184987T3 (es) Formas de administracion solidas de liberacion instantanea y procedimiento para su preparacion.
WO1998040097A3 (fr) Coronavirus respiratoire bovin utilise comme vaccin
WO1999057278A3 (fr) Immunisation et traitement anti-infectieux
ZA975586B (en) Recombinant vaccine for diseases caused by encapsulated organisms.
EP0663209A3 (fr) Médicament pour inhiber les effets des protéines amyloidogéniques.
DE69513760D1 (de) Auf Helicobacter pylori Katalase basierende immunisierende Zusammensetzung
AP2000001746A0 (en) Anti- first-pass effect compounds.
EP0862918A3 (fr) Agent thérapeutique pour traitement de la dermatite canine acharnée

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 503636

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1998949828

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2307000

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2307000

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 96161/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 09509961

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998949828

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 96161/98

Country of ref document: AU

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载